Lazard Asset Management
FHTX icon

Lazard Asset Management’s Foghorn Therapeutics FHTX Stock Holding History

Lazard Asset Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,433
Closed -$34K – 1978
2025
Q2 		$34K Sell
7,433
-2,375
-24% -$9.93K ﹤0.01% 2064
2025
Q1 		$35K Sell
9,808
-774
-7% -$3.53K ﹤0.01% 2053
2024
Q4 		$49K Buy
+10,582
New +$77.1K ﹤0.01% 1972
2024
Q2 		– Sell
-548
Closed -$3K – 2299
2024
Q1 		$3K Sell
548
-8,434
-94% -$46.8K ﹤0.01% 1917
2023
Q4 		$57K Buy
+8,982
New +$38.7K ﹤0.01% 1855

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Lazard Asset Management's FHTX Position: Q3 2025 in Review

Lazard Asset Management sold out of Foghorn Therapeutics (FHTX) in Q3 2025, closing a stake of 7,433 shares — an estimated $34K sold.

Lazard Asset Management first reported a position in FHTX in Q4 2023 and held it in 5 quarters. The position peaked at $57K in Q4 2023. 88 funds tracked by Wall St. Rank hold FHTX as of Q3 2025.

  • Lazard Asset Management reported no remaining Foghorn Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 7,433 Foghorn Therapeutics shares in Q3 2025, an estimated $34K.
  • Lazard Asset Management first reported a position in Foghorn Therapeutics in Q4 2023 and held it in 5 quarters.
  • Lazard Asset Management's Foghorn Therapeutics position peaked at $57K in Q4 2023.
  • 88 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.